CRISPR gene therapies should be widely adopted as a standard treatment option for sickle cell disease

What's this about?

People disagree about whether CRISPR gene therapy should become a usual choice for all people with sickle cell disease.

What supporters say

• A lasting cure could save money by cutting pain, hospital stays, blood gifts, and other care over a lifetime.
• Trials show that many patients had far fewer severe pain attacks after treatment.
• A cure-like choice could help people with severe disease who cannot get a close-match cell gift.
• CRISPR changes a patient's own blood stem cells, so the body makes more fetal hemoglobin.

What critics say

• Fair tests used few people, lacked a comparison group, and followed them for a short time.
• We do not yet know all the long-term risks of changing genes in blood cells.
• Treatment needs strong drug treatment first, plus expert centers and close care.
• The high price and need for expert centers could leave poorer patients behind.

How to read this

The number of points on each side does not show who is right; the strength of the proof matters more.

The bottom line

The proof does not yet support using CRISPR as a usual choice for everyone. It looks most useful for carefully chosen people with severe disease and many health crises.

CRISPR gene therapy could transform treatment for sickle cell disease, but the evidence does not yet support making it a routine choice for everyone. The strongest case is for carefully selected people with severe disease and repeated complications despite standard care.

The case for

The treatment can sharply reduce the painful crises that define severe sickle cell disease. In the pivotal study, 29 of 30 evaluable participants went at least 12 consecutive months without a vaso-occlusive crisis, and later follow-up suggests the benefit may continue beyond that period (see Figure 2). For patients facing repeated hospitalizations and severe pain despite existing treatments, that scale of improvement could justify offering the therapy as a standard option. 1

CRISPR also aims at the disease’s underlying cause rather than treating complications one at a time. Casgevy edits a patient’s own blood-forming stem cells to reactivate fetal hemoglobin, helping prevent red blood cells from sickling. Regulatory approval and laboratory and clinical evidence support the biological logic of this approach (see Figure 3). 2

There is also a significant unmet need. Hydroxyurea helps many patients, but it does not eliminate crises for everyone or resolve all concerns about long-term organ damage. A potentially curative treatment could be especially valuable for people with severe disease who cannot receive a matched-sibling transplant (see Figure 1). 4

The high upfront price may be defensible if the benefits last. Economic models suggest that preventing pain crises, hospital stays, transfusions and other complications could produce large lifetime health gains. Some analyses find gene therapy cost-effective compared with lifelong management, although those conclusions depend on its price and durability (see Figure 4). 3

The case against

The main concern is that the evidence is promising but still limited. The pivotal study was small, open-label and single-arm, with no randomized comparison against hydroxyurea, transplantation or other established treatments. Its participants had severe disease and were carefully selected, so the results cannot yet show how the treatment compares across the wider sickle-cell population. 5

The treatment is also far more demanding than taking a regular medicine. Patients must have stem cells collected, undergo laboratory manufacturing, receive intensive chemotherapy to clear space in the bone marrow, and then have the edited cells returned. This requires specialized centers, lengthy coordination and follow-up, and carries serious treatment-related risks. 6

Long-term safety remains unresolved. Because the therapy permanently changes blood-forming stem cells, regulators require extended monitoring for delayed cancers, abnormal cell growth, unintended genetic changes and other effects that may take years to appear. Current follow-up is not long enough to remove those concerns. 7

Wide use could also deepen existing inequalities. The treatment requires advanced manufacturing, hospital care, fertility counseling or preservation in some cases, and access to a small number of specialist centers. High prices, insurance restrictions and limited capacity could make it much easier to obtain for wealthy patients and well-resourced health systems than for underserved communities. 8

The bottom line

The evidence strongly supports CRISPR gene therapy as an important standard option for appropriately selected adolescents and adults with severe sickle cell disease, particularly those with recurrent crises despite established care. The short-term reduction in severe complications is substantial, and the treatment addresses the disease mechanism while meeting a major unmet need.

But the evidence does not support unconditional routine use for every patient. The strongest objections—limited comparative evidence and incomplete knowledge of lifetime genetic risks—are better supported than claims about broad population-wide effectiveness. The treatment’s value also depends on how long its benefits last, its price, safety monitoring, treatment capacity and whether access is distributed fairly. For now, targeted adoption is justified; universal adoption is premature.